Pharmaceutical formulation containing angiotensin-II receptor blocker

An angiotensin, receptor blocker technology, applied in the field of pharmaceutical preparations, can solve the problem of lack of antioxidants and the like

Inactive Publication Date: 2011-05-18
韩诺生物制约株式会社
View PDF7 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Hypertensive patients are often deficient in antioxidants in all tissues, although the presence of antioxidants in adequate amounts in the liver prevents liver damage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical formulation containing angiotensin-II receptor blocker
  • Pharmaceutical formulation containing angiotensin-II receptor blocker
  • Pharmaceutical formulation containing angiotensin-II receptor blocker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0148] Preparation of uncoated tablet containing angiotensin-II-receptor blocker

[0149] 1) Preparation of angiotensin-II-receptor blocker sustained-release granules

[0150] According to the content of ingredients shown in Table 1 below, Telmisartan, microcrystalline cellulose, sorbitol, meglumine and sodium hydroxide were sieved through a No. 35 sieve and mixed in a high-speed mixer for 5 minutes to prepare mixture. Meanwhile, polyvinylpyrrolidone was dissolved in purified water (70 mg / tablet) to prepare a binding solution, followed by kneading, granulation and drying. The dried material was placed in a fluid bed coater. Meanwhile, polyvinyl acetate was dissolved in a mixed solvent of ethanol and dichloromethane (2:8) (240 mg / tablet) to prepare a solution, which was then coated in a fluidized bed coater (GPCG-1: Glatt, Germany ) coated on the particles. After the coating process is completed, drying is performed to prepare angiotensin-II-receptor blocker sustained-...

Embodiment 2

[0153] Preparation of uncoated tablet containing angiotensin-II-receptor blocker

[0154] 1) Preparation of angiotensin-II-receptor blocker sustained-release granules

[0155] According to the ingredient content shown in Table 1 below, irbesartan, pregelatinized starch, lactose and croscarmellose sodium were sieved through a No. 35 sieve and mixed in a high-speed mixer for 5 minutes to prepare mixture. Meanwhile, Poloxamer 188 was dissolved in purified water (90 mg / tablet) to prepare a binding solution, followed by kneading, granulation and drying. The dried material was placed in a fluid bed coater. Meanwhile, cellulose acetate (acetyl 32.0%) and cellulose acetate (acetyl 39.8%) were dissolved in a mixed solvent (2:8) of ethanol and dichloromethane (800 mg / tablet) to prepare a solution, which was then The granules were coated in a fluid bed coater (GPCG-1: Glatt, Germany). After finishing the coating process, it is dried. The dried material, microcrystalline cellulo...

Embodiment 3

[0158] Preparation of uncoated tablet containing angiotensin-II-receptor blocker

[0159] 1) Preparation of angiotensin-II-receptor blocker sustained-release granules

[0160]According to the ingredient contents shown in Table 1 below, valsartan, microcrystalline cellulose, and crosslinked polyvinylpyrrolidone were sieved through a No. 35 sieve, and mixed in a high-speed mixer for 5 minutes to prepare a mixture. Meanwhile, polyvinylpyrrolidone was dissolved in purified water (100 mg / tablet) to prepare a binding solution, followed by kneading, granulation and drying. The dried material was placed in a fluid bed coater. Simultaneously, prepare respectively the solution of hydroxypropyl methylcellulose in purified water (70mg / sheet) and the mixed solvent (8: 2) of hydroxypropylmethylcellulose phthalate in ethanol and purified water ( 120mg / tablet). The granules were placed in a fluidized bed coater (GPCG-1: Glatt, Germany), and then coated in two steps with the prepared s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a pharmaceutical formulation containing an angiotensin-II receptor blocker and a release-control material as a pharmacologically active ingredient and a pharmaceutical formulation comprising an immediate-release compartment and an extended-release compartment. The immediate-release compartment contains an agent as a pharmacologically active ingredient for preventing and inhibiting hepatitis and the extended-release compartment has an angiotensin-II receptor blocker as a pharmacologically active ingredient. The formulation of the present invention maximizes the effectiveness on pharmacologically and clinically lowering blood pressure and preventing complications when taking the formulation, helps to avoid interaction with a drug which is metabolized by the same enzyme in the liver, and prevents and inhibits the incidence of drug-induced hepatitis which is caused by drug administration for a long time.

Description

technical field [0001] The present invention relates to pharmaceutical preparations which further enhance the efficacy of the drug when used as a single drug. In addition, the present invention relates to pharmaceutical preparations capable of reducing adverse side effects and further enhancing drug efficacy when administered simultaneously with other drugs. Background technique [0002] Hypertension is a condition serving as a major cause of death from cardiovascular diseases, and leads to incurable diseases such as cerebral stroke, myocardial infarction, congestive heart failure, and peripheral vascular disease. The blood pressure of the human body does not remain constant day and night. This is due to circadian biorhythmic patterns in blood pressure and heartbeat due to predictable changes in environmental and physiological differences that occur over a 24-hour period. The blood pressure of non-dipper patients whose blood pressure does not decrease during sleep suddenly...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/22A61K9/00A61K9/20A61K9/48
CPCA61K9/2081A61K9/2866A61K31/41A61K31/00A61K31/4178A61P9/12A61P31/12A61K9/20A61K9/28A61K47/38
Inventor 金圣旭田圣树曹英观具滋星A·R·李孙载云金正宅
Owner 韩诺生物制约株式会社
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap